Trial Profile
Phase I open-label dose escalation trial evaluating the safety and immunogenicity of sequential administration of recombinant DNA and adenovirus expressing L523S protein [lung cancer vaccine] in patients with early stage non-small cell lung cancer
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Lung cancer vaccine (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Corixa Corporation
- 08 Nov 2005 New trial record.